Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3401

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3401
---
 with Elkurt, Inc. to
three subsidiaries that house the applicable program: Ocean Chitorx, Inc. (for oncology), Ocean Sihoma, Inc. (for malaria) and Ocean
Chitofibrorx, Inc. (for fibrosis). On March 28, 2025, we also announced that the China National Intellectual Property Administration (CNIPA) has granted
a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic
effects on tumor cells.

These
issued patents and patent applications include:

    ●
    With
    respect to OCX-253, OCX-410, and OCX-909, our Ocean Chitorx, Inc. subsidiary obtained an exclusive sublicense from Elkurt, Inc.,
    or Elkurt, under Elkurt’s exclusive license from Brown University. Specifically, the Elkurt license includes four issued U.S.
    methods and compositions utility patents and twenty pending utility patent applications including applications in the United States,
    Canada, Europe, and Hong Kong. The issued patents have expected expiration dates in 2038, without accounting for any available patent
    term adjustments or extensions. Elkurt is a company formed by our scientific co-founders and members of our board of directors, Jack
    A. Elias, M.D., former Dean of Medicine and current Special Advisor for Health Affairs to Brown University, and Jonathan Kurtis,
    M.D., Ph.D., Chair of the Department of Pathology and Laboratory Medicine at Brown. 

38

    ●
    With
    respect to OCF-203, our Ocean Chitofibrorx, Inc. subsidiary obtained an exclusive sublicense from Elkurt under Elkurt’s exclusive
    license from Brown University. Specifically, this Elkurt license includes one issued U.S. methods and compositions utility patent
    and three pending utility patent application including applications in the United States, Canada, and Europe. 

    ●
    With
    respect to ODA-570, our Ocean Sihoma, Inc. subsidiary obtained an exclusive sublicense from Elkurt under Elkurt’s exclusive
    license from Rhode Island Hospital. Specifically, this Elkurt license includes eight issued patents including four U.S. patents,
    one European patent validated in seven countries, one South African patent, one African Regional Intellectual Property Organization,
    or ARIPO, patent; one Indian patent; and six pending utility patent applications including applications in the United States